Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 26Rectal Neoplasms 6Colonic Neoplasms 6Neoplasm Metastasis 5Parkinson Disease 4, Autosomal Dominant Lewy Body 3Advanced Solid Tumors 3Stomach Neoplasms 2Pancreatic Neoplasms 2Gallbladder Neoplasms 2Advanced Solid Tumors (Excluding Breast Cancer) 2Urologic Diseases 1Solid Tumor Cancer 1Renal Insufficiency 1Refractory Solid Tumors 1Pretreated Metastatic Colorectal Cancer 1Neoplasms 1Liver Neoplasms 1Liver Diseases 1Kidney Neoplasms 1Kidney Diseases 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Gastric Adenocarcinoma 1Digestive System Diseases 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1Carcinoma 1Breast Neoplasms 1Bile Duct Neoplasms 1Advanced or Metastatic Solid Tumors 1

Interventions

trifluridine tipiracil drug combination 1tipiracil 1Trifluridine 1Taxes 1Irinotecan 1Gastrectomy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Gastric Adenocarcinoma × trifluridine tipiracil drug combination × Clear all
NCT04074343 2024-02-02

TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma

University of California, Irvine

Phase 1 Completed
20 enrolled 9 charts
Gastrointestinal

Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡